
-
BeyondSpring Pharmaceuticals NASDAQ:BYSI BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. BeyondSpring's lead asset, plinabulin, a first-in-class agent as an immune and stem cell modulator, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and Phase 3 clinical programs in the prevention of CIN. The U.S. FDA granted Breakthrough Therapy designation to plinabulin for concurrent administration with myelosuppressive chemotherapeutic regimens in patients with non-myeloid malignancies for the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has strong R&D capabilities with a robust pipeline in addition to plinabulin, including three immuno-oncology assets and a drug discovery platform using the protein degradation pathway, which is being developed in a subsidiary company, Seed Therapeutics, Inc. The Company also has a seasoned management team with many years of experience bringing drugs to the global market. BeyondSpring is headquartered in New York City.
Location: | Website: www.beyondspringpharma.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
76.76M
Cash
2.922M
Avg Qtr Burn
-4.111M
Short % of Float
6.18%
Insider Ownership
15.21%
Institutional Own.
13.07%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Plinabulin Details Cancer, Lung cancer, Non-small cell lung carcinoma | NDA Submission | |
Plinabulin Details Cancer, Chemotherapy-induced neutropenia | NDA Submission | |
Plinabulin + PD-1 inhibitor + Etoposide/Platinum (EP) Details Cancer, Lung cancer, extensive-stage small-cell lung cancer (ES-SCLC) | Phase 2 Data readout |